Skye Bioscience Inc (SKYE)

[zenvesting]

NMUS is steering their development efforts right into that hot spot of abuse deterrent and opiod alternatives to pain managment that Dr. Gupta is talking about too, take note of slide #34 of their March 2018 slide deck (available on bottom of their homepage), their NB2111 program is now targeting "Pain Syndromes" more broadly than their previous "Chemotherapy Induced Neuropathy" target discussed in previous presentations and the development timeline has them ready for a clinical POC study early next year now!

Previously, they had their NB1222 for Chemotherapy Induced Nausea and Vomiting (CINV) was higher priority, but now it is "Prioritization Pending Further Market Analysis"....which I suspect means they are shopping for a partner to fund that now, to allow them to use their funds to pursue the big fish of "Pain Syndromes".

NMUS sure looks cheap relative to competitors when you consider the size of the markets they are going after.